Lai, T. Y. Y., Luk, F. O. J., Lee, G. K. Y., & Lam, D. S. C. (2012). Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Nature Publishing Group.
Citação norma ChicagoLai, T Y Y., F O J. Luk, G K Y. Lee, and D S C. Lam. Long-term Outcome of Intravitreal Anti-vascular Endothelial Growth Factor Therapy With Bevacizumab or Ranibizumab As Primary Treatment for Subfoveal Myopic Choroidal Neovascularization. Nature Publishing Group, 2012.
Citação norma MLALai, T Y Y., F O J. Luk, G K Y. Lee, and D S C. Lam. Long-term Outcome of Intravitreal Anti-vascular Endothelial Growth Factor Therapy With Bevacizumab or Ranibizumab As Primary Treatment for Subfoveal Myopic Choroidal Neovascularization. Nature Publishing Group, 2012.